The use of GLP-1 agonists and SGLT-2 inhibitors in patients with type II diabetes and established ASCVD was first recommended in the “Standards of Medical Care in Diabetes 2017” by the American Diabetes Association (ADA) [21]. Here, SLC5A2 is linked to diabetes mellitus.